Bupropion is effective in depression in narcolepsy

Area of Science:

• Neurology
• Psychiatry
• Sleep Medicine

Background:

• Narcolepsy is a rare neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.
• Current treatments for narcolepsy symptoms, including stimulants and antidepressants, offer limited efficacy and no definitive cure.

Purpose of the Study:

• To report a case of successful treatment of narcolepsy cataplexy syndrome with comorbid depression using bupropion.
• To evaluate the efficacy of bupropion in a patient unresponsive to conventional therapies.

Main Methods:

• A 58-year-old female diagnosed with narcolepsy cataplexy syndrome and depression was treated initially with imipramine and modafinil without improvement.
• Bupropion was initiated at 150 mg/day, with dosage escalated to 300 mg/day.
• Symptom severity was assessed using the Epworth Sleepiness Scale (ESS) and Beck Depression Inventory (BDI).

Main Results:

• The patient's ESS score was 14 and BDI score was 29 at baseline.
• Following bupropion treatment escalation to 300 mg/day, the patient became asymptomatic within 3 months.
• This represents the second reported case of a depressive narcoleptic patient responding positively to bupropion at this dosage.

Conclusions:

• Bupropion at 300 mg/day demonstrated significant efficacy in treating a patient with narcolepsy cataplexy syndrome and depression.
• This finding suggests bupropion may be a viable therapeutic option for narcolepsy patients with co-occurring depressive symptoms.
• Further research is warranted to confirm the efficacy and safety of bupropion in a larger cohort of narcolepsy patients.